Business
INOVIO Reports Positive Interim Phase 1/2 Results for INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis
Treatment with INO-3107 resulted in 16 of 21 (76%) participants with a reduction in number of surgical interventions compared with previous year; 6
About this update from Inovio Pharmaceuticals, Inc.
[{"type":"text","content":"Treatment with INO-3107 resulted in 16 of 21 (76%) participants with a reduction in number of surgical interventions compared with previous year; 6 participants required no surgical intervention during the trialINO-3107 demonstrated statistical significance based on clinical endpoint of reduction in overall number of surgical interventions compared with previous yearINO-3107 was found to be well-tolerated and immunogenicPLYMOUTH MEETING, Pa., Oct. 13, 2022 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and prevent infectious diseases, cancer, and diseases associated with HPV, today announced positive interim results from an ongoing Phase 1/2 clinical trial evaluating INO-3107 for the treatment of HPV 6 and HPV 11-associated Recurrent Respiratory Papillomatosis (RRP) in adults. In the first cohort of 21 participants, INO-3107 showed a statistically significant improvement in the clinical endpoint of the number of surgical interventions needed to control papilloma growth. INO-3107 was also observed to be well-tolerated and immunogenic in the trial. INO-3107 received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) in July 2020.\nDr. Jacqueline Shea, INOVIO's President and CEO, said, \"RRP is a debilitating, often life-long condition for which surgery is the standard of care and there are no currently FDA-approved therapeutic vaccines or drugs. The positive results observed in this trial are a step toward potentially shifting the treatment paradigm for RRP and substantially improving the quality of life for patients suffering from its symptoms and the repeated surgeries needed to control them. As a potential first-in-class therapeutic candidate, INO-3107 is building on our body of work indicating that DNA medicines have the potential to treat HPV-associated diseases.\"\nDr. Ted Mau, Professor of Otolaryngology, Head and Neck Surgery at UT Southwestern Medical Center and investigator for INOVIO's RRP Phase 1/2 clinical trial, said, \"These preliminary results show great promise in this new therapy for patients with RRP. For our patients who have required multiple surgeries a year, and especially those who have done so for many years of their lives, this is a potential game changer.\"\nAbout the Trial\nINO-3107 was evaluated in...